Elanco Animal Health (ELAN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Voting matters and shareholder proposals
Election of two Class I and three Class II director nominees is up for vote at the annual meeting.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026 is proposed.
Advisory vote on executive compensation for named executive officers is included.
Board of directors and corporate governance
Nominees for Class I directors are Kapila Anand and Paul Herendeen.
Nominees for Class II directors are Michael Harrington, Lawrence Kurzius, and Kirk McDonald.
Executive compensation and say-on-pay
Shareholders are asked to provide an advisory vote on the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Elanco Animal Health
- Q1 2025 saw 4% organic growth, raised guidance, and accelerated debt paydown on strong innovation.ELAN
Q1 20259 Jul 2026 - Innovation and operational efficiency drive growth and margin expansion across pet and farm segments.ELAN
Piper Sandler 37th Annual Healthcare Conference8 Jul 2026 - 2024 saw organic growth, margin gains, and debt reduction; 2025 targets innovation-led expansion.ELAN
Q4 20248 Jul 2026 - Blockbuster launches and innovation pipeline drive strong growth and sustainability in 2025.ELAN
43rd Annual J.P. Morgan Healthcare Conference 20258 Jul 2026 - Innovation pipeline and global reach drive strong growth and raised financial targets.ELAN
46th Annual William Blair Growth Stock Conference8 Jun 2026 - Innovation and resilient pricing drive strong growth in animal health and farm segments.ELAN
Stifel Jaws & Paws Conference 202627 May 2026 - Strong growth, innovation, and all proposals approved, with new blockbusters targeted by 2031.ELAN
AGM 202621 May 2026 - Q1 2026 revenue up 15% to $1.371B, with raised guidance and strong innovation momentum.ELAN
Q1 202612 May 2026 - Innovation and global reach drive strong growth and margin stability in animal health.ELAN
Investor presentation6 May 2026